Detailed information
| LncRNA Name | SOX2OT |
| Variant Type | transcript variant |
| Variant ID | SOX2OT variant 7 |
| Species | human |
| Circulating | ✕ |
| Survival | ✓ |
| CeRNA | ✕ |
| Methylation | ✕ |
| Enhancer | ✕ |
| Drug | ✓ |
| Disease/Trait | osteosarcoma |
| LncRNA Target Gene | NA |
| Tissue | cell lines (U2OS and SaoS2, U-87 MG ) |
| Experiment | qPCR, Western blot, in vitro knockdown |
| Function Description | EGCG targeting LncRNA SOX2OT variant 7 produced synergistic effects with Doxorubicin on osteosarcoma cell growth inhibition. On the one hand, EGCG could reduce the Doxorubicin-induced pro-survival autophagy through decreasing SOX2OT variant 7 to improve the growth inhibition of Doxorubicin. On the other hand, EGCG could partially inactivate Notch3/DLL3 signaling cascade targeting SOX2OT variant 7 to reduce the stemness then abated drug-resistance of osteosarcoma cells. |
| Pubmed ID | 29475441 |
| Year | 2018 |
| Title | SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition. |
| External Links | |
|---|---|
| Links For SOX2OT | GeneCards HGNC NONCODE LncRNAWiki lncrnadb |
| Links For osteosarcoma | OMIM Cosmic |
| Links For SOX2OT variant 7 | dbSNP ClinVar OMIM |